ZBH — Zimmer Biomet Holdings, Inc.
Healthcare · ETF XLV · as of 2026-09-23
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Zimmer Biomet Holdings, Inc.
NYQ
Healthcare · Medical Devices
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to fa...
Price & today
$90.88
ATR(14) 2.86 (3.14%)
| Stock today | -3.30% |
| Sector ETF today | -0.64% |
| Residual (stock-specific) | -2.66% |
Sector correlation
| 20-day correlation with XLV | 0.49 |
| 60-day correlation with XLV | 0.57 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $94.60 |
| 20 EMA | $95.74 |
| 50 EMA | $95.33 |
| EMA stack | NEUTRAL |
| RSI(14) | 37.3 |
| 52-week high distance | -16.08% |
| 52-week low distance | +13.84% |
Signals
| Market F&G | 44.9 |
| Bull% | 13.8% |
| OVTLYR status | SELL (16d) |
| Sector rank | #445 |
| Next earnings | 2026-11-03 (BMO, 40d) |
MarketSmith metrics - our compute
RS Rating
19.0
ADR%
2.8
RMV (tight)
31.0
Ext (ATR>20EMA)
-1.7
Rel Vol
137.0%
U/D 50d
1.03
U/D 25d
0.83
Accum/Dist 25d
2 / 3
EPS YoY
+0.0%
LoD dist
35.0
Off 52w High
15.0%
Above 52w Low
14.9%
1W / 1M
-6.1 / -10.0
Avg $Vol 50d
208.7M
Mkt Cap (B)
17.6
Trend 8/8
no
Leads Group
no
Sector XLV
+0.6% 1W
Base len (VCP)
16wk (6/21)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
23.5
Fwd P/E
10.1
PEG
0.6
Price/Book
1.3
Profit margin
9.0%
ROE
6.1%
Debt/Equity
59.8
Rev growth
+9.3%
Analyst target
$99 (+8%)
Analyst rating
HOLD
Institutional %
105.1%
Insider %
0.2%
Float %
99.7%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
67 / 146
Industry
Medical Devices
Float
192.9M
Float turnover 20d
1.0%
Avg $Vol 20d / 50d
187.4M / 208.7M
Days to cover
5.1
Short % float
6.8%
Institutional %
105.1%
Weinstein stage
1
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Oct-24 | 1.74 | +5% | 1,824.2 | +4% |
| Feb-25 | 2.31 | +5% | 2,023.2 | +4% |
| May-25 | 1.81 | -7% | 1,909.1 | +1% |
| Aug-25 | 2.07 | +3% | 2,077.3 | +7% |
| Nov-25 | 1.90 | +9% | 2,001.4 | +10% |
| Feb-26 | 2.42 | +5% | 2,243.8 | +11% |
| Apr-26 | 2.09 | +15% | 2,086.7 | +9% |
| Aug-26 | 2.07 | +0% | 2,177.0 | +5% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 03 · Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? Zacks Investment Research
- Sep 03 · 1 Profitable Stock to Keep an Eye On and 2 That Underwhelm Yahoo
- Sep 02 · 1 Value Stock with Impressive Fundamentals and 2 We Question Yahoo
- Sep 02 · ISRG Stock: The Best House On The Block Costs The Most Yahoo
- Sep 01 + Zimmer Biomet - Showing Signs Of Life Seeking Alpha
- Sep 01 · Zimmer Biomet - Showing Signs Of Life SeekingAlpha
- Aug 31 + Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term Zacks Investment Research
- Aug 28 · Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 Yahoo